Drugs / IMM0306
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04746131 | Jan 2021 → Apr 2024 | B-cell non-Hodgkin lymphoma | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Suspended | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT05771883 | May 2023 → May 2025 | B-cell non-Hodgkin lymphoma | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Unknown | No outcome recorded |
| Phase 1/2 | NCT05805943 | Mar 2020 → May 2025 | B-cell non-Hodgkin lymphoma | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Unknown | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT07621939 | Jul 2026 → May 2030 expected | immunoglobulin G4-related sclerosing disease | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Not yet recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07355283 | Feb 2026 → Jul 2028 expected | B-cell neoplasm | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Not yet recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IMM0306 | “Amulirafusp alfa (IMM0306) is a fusion protein of CD47 binding domain of signal-regulatory protein alpha (SIRPα) with CD20 monoclonal antibody on both heavy chains.” PMID 39696680 ↗ Dec 2024 |
| Known as | Amulirafusp Alfa | “Amulirafusp alfa (IMM0306) is a fusion protein of CD47 binding domain of signal-regulatory protein alpha (SIRPα) with CD20 monoclonal antibody on both heavy chains.” PMID 39696680 ↗ Dec 20241“IMM0306 (Amulirafusp Alfa) will be administered once weekly” NCT07355283 ↗ |
| Modality | Protein / enzyme biologic | “IMM0306 is a fusion protein of CD20 mAb with the CD47 binding domain of SIRPα.” NCT05771883 ↗ |
| Route | Intravenous | “through intravenous administration weekly up to 52 weeks” NCT04746131 ↗ |
| Target | CD47 | “Amulirafusp alfa (IMM0306) is a fusion protein of CD47 binding domain of signal-regulatory protein alpha (SIRPα) with CD20 monoclonal antibody on both heavy chains.” PMID 39696680 ↗ Dec 2024 |